Modern approaches to the treatment of chronic lymphocytic leukemia: chemoimmunotherapy, targeted therapy, and minimal residual disease assessment
Keywords:
chronic lymphocytic leukemia, chemoimmunotherapy, targeted therapy, minimal residual disease, free light chains, immunophenotyping, FCR regimenAbstract
Chronic lymphocytic leukemia (CLL) is one of the most common B-cell lymphoproliferative disorders characterized by the progressive accumulation of monoclonal CD5+, CD19+, and CD23+ lymphocytes in the peripheral blood, bone marrow, lymph nodes, liver, and spleen. Over the past two decades, therapeutic strategies for CLL have evolved significantly, transitioning from conventional chemotherapy to chemoimmunotherapy and, subsequently, to targeted molecular therapies. The fludarabine, cyclophosphamide, and rituximab (FCR) regimen has long remained the standard first-line treatment for fit patients, demonstrating high response rates and prolonged progression-free survival. However, the development of Bruton tyrosine kinase inhibitors, BCL-2 inhibitors, and phosphoinositide 3-kinase inhibitors has substantially changed the therapeutic landscape.
References
1.Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia: a randomized phase III trial. Lancet. 2010;376:1164–1174.
2.Eichhorst B, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil in elderly patients with advanced chronic lymphocytic leukemia. Blood. 2009;114:3382–3391.
3.Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukemia. Lancet. 2007;370:230–239.
4.Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381:432–443.
5.Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107–1120.
6.Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–223.
7.Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311–322.
8.Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997–1007.
9.Thompson PA, Tam CS, O’Brien SM, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in CLL. Blood. 2016;127:303–309.
10.Rawstron AC, Bottcher S, Letestu R, et al. Improving efficiency and sensitivity: European Research Initiative in CLL recommendations for flow cytometric MRD analysis. Leukemia. 2013;27:142–149.